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Background: Combination therapy should be prescribed to patients with moderate to
severe asthma after daily long-term treatment with inhaled inhaled corticosteroids (ICS)
has been tried without obtaining adequate control and it is not indicated to be used as first
line treatment in asthma.
Objectives: To describe the use of combination therapy for the treatment of asthma and
to evaluate to which extent it is prescribed as recommended.
Methods: A cohort of 14 559 new users of a combination therapy identified between
January 1, 2000 and September 30, 2003 was selected from beneficiaries of the Re´gie de
l’assurance maladie du Que´bec. We evaluated whether the combination therapy was
prescribed according to the Canadian Asthma Guidelines. A logistic regression analysis was
also performed to identify patient’s and physician’s characteristics associated with the
adherence to the recommendations of the Canadian Asthma Guidelines for the prescription
of a combination therapy.
Results: Only 40% of users of combination therapy filled a prescription of ICS in the year
preceding the initiation of the therapy and this proportion decreased by 21.8% from 2000
to 2003. Patients who received their first combination therapy in an emergency
department were less likely to have used ICS previously, but patients treated by a
respiratory physician and patients with co-morbidities, markers of asthma severity and
markers of uncontrolled asthma were more likely to have used ICS previously.Copyright & 2007 Published by Elsevier Ltd. All rights reserved.
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Combination therapy in asthma 1917Conclusion: Combination therapy has not been used according to the Canadian Asthma
Guidelines in a large proportion of patients.
Crown Copyright & 2007 Published by Elsevier Ltd. All rights reserved.Introduction
Current evidence indicates that daily long-term control
medications are necessary to prevent exacerbations and
chronic symptoms for all patients with persistent asthma,
whether asthma is mild, moderate, or severe.1–3 According
to Canadian and International Guidelines (GINA) for asthma
management, inhaled corticosteroids (ICS) are preferred
because they are the most effective anti-inflammatory
medication available for treating the underlying inflamma-
tion characteristic of persistent asthma.1–3
A stepwise approach is recommended for the treatment
of asthma based on the underlying severity of symptoms.1–4
When asthma is not optimally controlled with ICS alone, the
addition of long-acting b2-agonists (LABA) to ICS is recog-
nised as the most effective therapy to control moderate to
severe asthma.2 On the other hand, LABA should not be used
in monotherapy and should not be initiated before a
treatment with ICS has been tried.2
Two medications, ICS and LABA, have been combined into
one inhaler (combination therapy): salmeterol plus flutica-
sone and formeterol plus budesonide. Combination therapy
should be prescribed to patients with moderate to severe
asthma after daily long-term treatment with ICS has been
tried without obtaining adequate control and it is not
indicated to be used as first line treatment in asthma.5 To
our knowledge no study has described the use of combina-
tion therapy for the treatment of asthma in real clinical
practice.
The purpose of this study was to describe the use of
combination therapy for the treatment of asthma and to
evaluate to which extent it is prescribed as recommended,
i.e. after ICS in monotherapy have been tried. We also
investigated patient’s and physician’s characteristics asso-
ciated with adherence to guidelines’ recommendations.
Methods
Source of data
This study was based on data retrieved from the adminis-
trative databases of the Re´gie de l’assurance maladie du
Que´bec (RAMQ). These databases contain claims data on
health care services provided to Quebec residents. With
unique encrypted health insurance number, the four follow-
ing databases administered by the RAMQ were merged at the
patient level: drug plan admissibility, beneficiary informa-
tion, prescription and medical services claims. The Medical
Services Database includes residents covered by the
provincial health care insurance (essentially the whole
population of Que´bec) and the Prescription Drug Database
includes residents covered by the RAMQ drug insurance plan,
which represents about 43% of the total population of
Que´bec.6 In 2002, this drug plan was covering 3 154 465people classified into three groups: welfare recipients
(545 651 individuals), seniors of 65 years old or more
(883 483 individuals), and people under 65 years old who
do not have access to a private group insurance (1 725 331
individuals).
The RAMQ databases provide also socio-demographic
information such as age, gender, receipt or not of social
assistance, area of residence and date of death, when
applicable. The drug plan admissibility database provides
information on the duration of the admissibility to the RAMQ
drug insurance plan. For all prescription drugs dispensed to
beneficiaries of the RAMQ drug plan, the Prescription Drug
Database contains information such as the unique patient’s
identifier, drug name, dose, dosage form, quantity of drug
dispensed, prescription duration, prescription dispensation
date and the specialty of the prescribing physician. For each
medical service dispensed, the Medical Services Database
contains information on the date and place where it was
dispensed (hospital, emergency department [ED], or med-
ical clinic), the ICD-9 diagnosis code, the specialty, year and
place of graduation of the treating physician and the unique
patient’s identifier. The accuracy of the RAMQ prescription
claims database as a source of information on drug use in
pharmacoepidemiological research has been established.7Study cohort
This study was based on a cohort of new users of
combination therapy aged between 16 and 44 years old
selected from the RAMQ databases between January 1, 2000
and September 30, 2003. To enter the cohort, patients had
to fulfill the following criterion: (1) having at least one
prescription of a combination therapy filled between
January 1, 2000 and September 30, 2003 (the first
prescription filled on or after January 1, 2000 will be
referred to as the index date); (2) being aged between 16
and 44 years old on the index date; (3) being covered by the
RAMQ drug plan for at least one year prior to the index date;
(4) filled no prescription of a combination therapy for at
least one year preceding the index date; (5) filled no
prescription for acetylcysteine, epinephrine racemique,
ipratropium bromide, ipratropium bromide/salbutamol,
ipratropium bromide/fenoterol, morphine, pancrelipase,
pancreatin, tobramycin injectable in the year preceding
the index date, as an attempt to eliminate patients with
COPD and cystic fibrosis. During the years 2000–2002 only
the salmeterol/fluticasone combination product (Advair)
was reimbursed by the RAMQ drug plan and in 2003 both
products (Advair and Symbicort (formeterol/budesonide))
were reimbursed by the RAMQ. However, patients who
initiated a treatment with a combination therapy (Symbi-
cort only, Advair was on the regular list) between November
2002 and January 2003 were excluded since during that
period combination products were removed from the regular
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under certain restricted conditions.
Patients entered the cohort on the date of the first
prescription of a combination therapy filled on or after
January 1, 2000 (index date). Data on prescription and
medical services were obtained from the RAMQ for all cohort
members for the period between January 1st 1999 and
September 30, 2003.
Adherence to prescribing recommendations
Main criteria
Patients were considered adherent to the recommenda-
tions1,2 if they filled at least one prescription of an ICS in the
year preceding the filling of the first prescription of a
combination therapy (index date).
Strict criterion
In a second analysis, patients were considered adherent
with the recommendations if they used ICS regularly (i.e. at
least 75% of the time) in the year preceding the index date.
To assess this criterion the duration of each prescription of
ICS filled in the year preceding the index date was summed.
The percentage of time with an ICS therapy was then
categorized: 0%; 40–25%; 425–50%; 450–75%; 475% of
the time.
Factors associated with non-adherence
We investigated whether pre-defined patient’s and physi-
cian’s characteristics were associated with adherence
(according to the main criteria) to recommendations for
the prescription of combination therapy.
Patient’s characteristics
The patient’s characteristics under study were regrouped
into four categories. First, socio-demographic variables
including age at index date, gender, region of residence
(rural/urban), receipt of social assistance (yes/no) and
number of co-morbidities. A patient was identified as having
a co-morbidity if he or she filled at least two prescriptions of
a medication indicated to treat a chronic disease. Cardio-
vascular disease (CVD), cancer, epilepsy, CNS disease,
anxiety and depression, gastrointestinal disease and dia-
betes were considered in the analysis.
Second, variables associated with the prescription of the
combination therapy included the year of treatment
initiation, the daily dose of ICS in the first prescription
(p250 versus 4250mcg per day in fluticasone equivalent),
and the place where the combination therapy was first
prescribed (medical clinic, ED, hospital or other).
Third, variables related to the treatment of asthma in the
year preceding the index date included the presence or
absence of an asthma diagnosis recorded in the RAMQ
database, the use of oral corticosteroids (yes/no), the use of
LABA (yes/no) and the average number of doses of short-
acting inhaled b2-agonist per week (0, 40–3, 44–10,
410 doses). To calculate the mean weakly doses of short-
acting inhaled b2-agonist we developed an algorithm on the
basis of the name and formulation of the product pre-
scribed, prescription renewals, quantity of medicationdispensed, duration of the prescription, and length of time
between renewals. Equivalencies between the different
medications dispensed were assessed by a clinical pharma-
cist specialized in respiratory health.8
Fourth, variables related to the use of health care
services in the year preceding the index date included ED
visit for asthma (yes/no), hospitalization for asthma (yes/
no) and the filling of an antibiotic prescription at plus or
minus five days from the index date (yes/no).Physician’s characteristics
The characteristics of the physician who prescribed the
combination therapy on the index date were investigated.
The variables under study were the specialty of the treating
physician (respiratory physician, family physician and other
specialists), and the year and university of graduation.Statistical analyses
Main analyses
We first estimated the proportion of patients with a new
combination therapy who fulfilled the main criterion of
adherence to the recommendations. We also estimated the
proportion of patients with a new combination therapy who
fulfilled the strict criterion of adherence. This analysis was
restricted to patients who were covered by the RAMQ drug
plan for at least one year prior to the index date in order to
account for prescriptions of ICS filled before the year
preceding the index date but used during that year. In
addition, we estimated the proportion of patients who filled
at least one prescription of a short-acting inhaled b2-
agonist, a LABA and any medication indicated in the
treatment of asthma (ICS, LABA, short-acting b2-agonist,
theophylline or anti-leukotriene) in the year preceding the
index date. The precision of these estimates was assessed
with 95% confidence intervals. These proportions were
estimated separately for the years 2000–2003 in order to
investigate the presence of a trend over time.
Finally, a logistic regression analysis was performed to
identify patients’ and physicians’ characteristics associated
with the adherence to the recommendations for the
prescription of a combination therapy (main criterion).Sensitivity analyses
Two sensitivity analyses were performed to validate the
robustness of our criterion for adherence. For the first
sensitivity analysis, the main criterion was applied over a
period of two years prior to the index date. A patient was
thus considered having a treatment in adherence to the
recommendations if he or she filled at least one prescription
of ICS in the two years preceding the index date. This
analysis was restricted to patients who were covered by the
RAMQ drug insurance plan for at least two years prior to the
index date and did not receive any prescription of a
combination therapy during the same period. For the second
sensitivity analysis, the estimation of the proportion of
patients in adherence with the recommendations was
restricted to patients who had at least one asthma diagnosis
in the year prior to the index date.
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Table 1 Patients’ characteristics prior to the first
prescription of a combination therapy (n ¼ 14 559).
Number (%)
Socio-demographic variables
Age (years)
16–24 3108 (21.3)
25–34 4713 (32.4)
35–44 6738 (46.3)
Male 5402 (37.1)
Living in urban area 11 275 (77.4)
Receiving social assistance 5876 (40.4)
Number of co-morbidities
o5 14 437 (99.2)
X5 122 (0.8)
1st prescription of a combination therapy
Years
2000 1836 (12.6)
2001 3881 (26.7)
2002 5070 (34.8)
2003 3772 (25.9)
Dose of ICS (mcg per day in fluticasone equivalent)
4250 13 546 (93.0)
Site of prescription
Clinic 10 787 (74.1)
ED 1323 (9.1)
Hospitalisation 252 (1.7)
Other 2197 (15.1)
Asthma related variables in the year preceding the index
date
X1 asthma diagnosis 7527 (51.7)
X1 prescription of oral corticosteroids 1231 (8.5)
Short-acting b2-agonist (number of doses
per week)
0 8634 (59.3)
40–10 2956 (20.3)
410 2969 (20.4)
X1 ED visit for asthma 1314 (9.0)
X1 hospitalisation for asthma 227 (1.6)
LABA without any form of ICS 137 (0.9)
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We initially identified 85 393 patients aged 16 years old or
more from the RAMQ databases who filled at least one
prescription of a combination therapy from January 1, 2000
to September 30, 2003. We then selected the patients who
were aged between 16 and 44 years old when they filled
their first prescription of a combination therapy. From these
19 456 patients, we excluded 3850 patients because they
had less than a year of RAMQ drug coverage before the index
date and 942 subjects because they filled at least one
prescription of a medication indicated for COPD or cystic
fibrosis in the year preceding the index date. We also
excluded 105 patients because they received their first
prescription of a combination product between November
2002 and January 2003 while this medication was on the
restricted List of medications of Que´bec. The cohort of new
users of a combination therapy was thus formed of 14 559
patients.
Table 1 shows the patients’ characteristics prior to the
first prescription of a combination therapy. Forty-six percent
of the patients were aged between 35 and 44 years old,
37.1% were male, 40.4% were receiving social assistance and
0.8% had more than 5 co-morbidities. The vast majority of
the patients (93.0%) started their combination therapy with
a dose of ICS larger than 250mcg per day in fluticasone
equivalent and 74.1% of patients had their first combination
therapy prescribed in a medical clinic. Only half of the
patients (51.7%) had an asthma diagnosis recorded in the
RAMQ database in the year preceding the index date.
Regarding asthma treatment, we observed that 8.5% filled at
least one prescription of oral corticosteroids, 20.4% took
more than 10 doses per week of short-acting b2-agonists,
less than 1% had LABA without ICS, 9.0% had an emergency
visit for asthma and 1.6% were hospitalized for asthma in the
year preceding the index date.
The use of ICS in the year preceding the first prescription
of a combination therapy is presented in Table 2. We
observed, overall, that 39.6% of patients filled at least one
prescription of an ICS in the year preceding the first
prescription of a combination therapy. We also observed
that this proportion decreased over time, being 55.0% in
2000 and 33.2% in 2003. We observed the same phenomenon
for all the other asthma medications under study.
The results of the analysis of the determinants of the use
of ICS prior to the index date are presented in Table 3. The
logistic regression model (n ¼ 14 559) revealed that patients
aged between 25 and 34 years old were less likely to use ICS
prior to the index date, while patients receiving social
assistance and patients having two co-morbidities or more
were more likely to use ICS prior to the index date. We also
observed that patients were progressively, over calendar
time, less likely to have used ICS prior to the first
prescription of a combination therapy. Patients who re-
ceived their first combination therapy in an ED were less
likely than others to have used ICS previously, while patients
who initiated their combination therapy with 251mcg per
day or more of ICS (in fluticasone equivalent) and patients
who had their combination therapy prescribed by a
respiratory physician were more likely to use ICS prior to
the index date. Moreover, we observed that patients who
had a diagnosis of asthma and patients with markers ofuncontrolled or severe asthma in the year preceding the
initiation of the combination therapy, such as the use of oral
corticosteroids, LABA and an ED visit for asthma, were more
likely to have used ICS prior to the combination therapy.
Finally, we found that patients who had more than one
prescribing physician were more likely while patients who
filled a prescription for an antibiotic on or close to the index
date were less likely to have used ICS previously.
In order to further study the use of ICS preceding the first
prescription of a combination therapy, we estimated the
proportion of patients using ICS regularly (75% of the time or
more). For the years 2000–2003 combined, we observed that
only 2.5% of patients used ICS more than 75% of the time,
38.9% used ICS less than 75% of the time and 58.6%
had not filled any prescription of ICS in the year preceding
the index date.
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Table 2 Use of asthma medications in the year preceding the first prescription of a combination therapy (index date).
Year of first prescription of a combination therapy
2000 2001 2002 2003 2000–2003
Number of patients 1836 3881 5070 3772 14 559
Patients with at least one dispensed prescription in percent [95% CI]
ICS 55.0 [52.7; 57.3] 42.8 [41.3; 44.4] 36.3 [34.9; 37.6] 33.2 [31.7; 34.7] 39.6 [38.8; 40.4]
Short-acting
b2-agonist
62.7 [60.5; 64.9] 52.1 [50.5; 53.6] 45.6 [44.2; 46.9] 41.3 [39.7; 42.8] 48.4 [47.5; 49.2]
LABA 17.7 [16.0; 19.4] 8.3 [7.4; 9.2] 6.8 [6.1; 7.5] 9.7 [8.8; 10.7] 9.3 [8.9; 9.8]
Any asthma
medicationa
69.9 [67.8; 72.0] 58.7 [57.1; 60.2] 52.9 [51.6; 54.3] 49.7 [48.1; 51.3] 55.8 [55.0; 56.6]
aAsthma medications: ICS, SABA, LABA, anti-leukotriene, theophyllines and oral corticosteroids.
Table 3 Patients’ and physicians’ characteristics associated with the use of ICS prior to the first prescription of a
combination therapy (n ¼ 14 559).
% users of ICS Adjusted OR 95% CI
Socio-demographic variables
Age (years)
16–24 39.8 Reference
25–34 39.0 0.88 0.78; 1.00
35–44 39.8 1.01 0.90; 1.15
Gender
Female 39.6 Reference
Male 39.7 0.98 0.89; 1.08
Region of residence
Urban 40.2 Reference
Rural 37.5 1.03 0.92; 1.15
Social assistance
No 35.5 Reference
Yes 45.8 1.40 1.27; 1.55
Number of co-morbidities
0 35.7 Reference
1 43.1 1.03 0.91; 1.17
2–4 49.4 1.15 1.01; 1.32
5+ 71.3 2.79 1.69; 4.61
1st prescription of a combination therapy
Year
2000 55.0 Reference
2001 42.8 0.90 0.77; 1.05
2002 36.3 0.76 0.66; 0.88
2003 33.2 0.66 0.56; 0.79
Dose of ICS (mcg per day in fluticasone
equivalent)
p250 29.1 Reference
4250 40.4 1.36 1.13; 1.64
Site of prescription
Clinic 39.7 Reference
ED 29.5 0.69 0.58; 0.82
Hospitalisation 55.6 0.74 0.52; 1.07
Other 43.6 1.23 1.09; 1.41
Asthma related variables in the year preceding the index date
X1 asthma diagnosis
No 21.5 Reference
Yes 56.4 2.04 1.85; 2.25
M.-C. Breton et al.1920
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Table 3 (continued )
% users of ICS Adjusted OR 95% CI
X 1 oral corticosteroids
0 36.4 Reference
X 1 rx 73.8 1.27 1.07; 1.51
Short-acting b2-agonists (number of
doses per week)
0 16.0 Reference
40–3 62.6 6.05 5.21; 7.01
43–10 69.7 7.83 6.89; 8.89
410 80.7 12.03 10.66; 13.58
LABA
No 34.4 Reference
Yes 89.9 10.11 8.21; 12.45
ED visit for asthma
No 35.7 Reference
Yes 79.1 1.71 1.42; 2.06
Hospitalisation for asthma
No 38.9 Reference
Yes 80.6 0.74 0.48;1.14
Number of prescribers
0–1 16.7 Reference
2 36.0 2.08 1.81; 2.39
+3 52.6 3.02 2.67; 3.43
Antibiotics (75 days around the index date)
No 44.0 Reference
Yes 23.9 0.75 0.66; 0.84
Physician’s characteristics
Speciality
Family physician 36.3 Reference
Respiratory physician 70.4 1.58 1.32; 1.88
Other specialist 49.8 1.48 1.19; 1.84
Year of graduation
69 or less 34.6 0.84 0.69; 1.01
70’s 42.2 0.93 0.81; 1.07
80’s 39.0 0.93 0.81; 1.07
90’s or more 37.0 Reference
Missing 48.9 1.36 0.93; 1.98
University of graduation
Montreal 40.4 Reference
Laval 37.5 0.97 0.86; 1.09
Mcgill 37.6 0.95 0.76; 1.17
Shebrooke 40.7 0.95 0.79; 1.14
Other Canadian or US universities 46.3 0.78 0.59; 1.02
Missing 40.9 0.97 0.85; 1.10
Combination therapy in asthma 1921In the first sensitivity analysis we observed that 50.3% of
patients (n ¼ 12 732) filled at least one prescription of an ICS
within the two years preceding the index date, resulting in a
10% increase as compared with the primary analysis which
was based on the year preceding the index date. We also
observed in this sensitivity analysis that the percentage of
patients using ICS prior to the index date decreased over
time, from 65.1% in 2000 to 43.5% in 2003.
The second sensitivity analysis was performed among
patients who had at least one diagnosis of asthma recorded
in the RAMQ databases in the year preceding the index date.The percentage of patients using ICS found in this sub-group
of 7527 patients was higher than those found in the first
sensitivity analysis and the main analysis, with 56.4% of the
patients who filled at least one prescription of an ICS in the
year preceding the index date.Discussion
The results of this study demonstrate that only 40% of new
users of a combination therapy filled a prescription of ICS in
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2000 and 2003. Another important finding of this study is
that the percentage of patients using ICS prior to their first
prescription of a combination therapy decreased by 21.8%
from 2000 to 2003.
Even when we looked back two years prior to the initiation
of a combination therapy we found that only 50% of the
patients had filled a prescription of ICS prior to treatment
initiation. These results show that combination therapies
tend to be initiated for a large proportion of patients early in
the course of the treatment for asthma and are not used as
recommended by the Canadian Asthma Guidelines,2 i.e. when
asthma is not well controlled with a low to moderate dose of
ICS. In this study, however, it is not possible to differentiate
between patients who receive a prescription of ICS and did
not fill it and patients who did not receive such a
prescription. Even though the Canadian Asthma Guidelines
are not clear on this issue, someone may argue that patients
who present with moderate to severe asthma symptoms may
benefit from combination therapy even if he or she did not
use ICS previously. However, in our population, patients with
markers of moderate to severe exacerbations (filled pre-
scription of oral corticosteroids, emergency room visit and
hospitalization for asthma) and no use of ICS prior to the
initiation of the combination therapy represented only 5.5%
of the patients who started a combination therapy.
We also performed an analysis to identify patients’ and
physicians’ characteristics that might explain, at least in
part, how the combination products were used or pre-
scribed. From this analysis we found that patients aged
between 25 and 34 years old were less likely to use ICS prior
to their first prescription of a combination product. On the
other hand, patients with markers of asthma severity and
uncontrolled asthma prior to the initiation of the combina-
tion therapy were more likely to have used ICS previously.
Moreover, we found that patients who receive their first
prescription of a combination therapy in an ED or from a
family physician and patients who did not receive a medical
service for asthma in the year prior to the combination
therapy, as well as patients who filled a prescription of
antibiotics close to the date of their first prescription of a
combination therapy were less likely to have used ICS
previously. These findings might indicate that a non-
negligible proportion of patients receive the combination
therapy for an indication other than asthma and might
explain the absence of a prescription of ICS prior to the
filling of a combination therapy.
Having this study based on data retrieved from a large
administrative database has several advantages. Firstly, we
were able to reconstruct a large cohort of new users of
combination therapy, providing precise estimates and high
statistical power to identify determinants of adherence to
guidelines for the prescription of a combination therapy.
Secondly, the results of our study reflect the real clinical
practice, avoiding a potential Hawthorne effect that could
be present if prescribing physicians and patients would be
aware that they were under examination.9,10 Thirdly, by
assessing medication use through prescription refills we
avoided recall bias: the database provides prospectively
collected full details on name, dose, and amount of drugs
dispensed, information that is almost impossible to obtain
by questionnaire after time has elapsed.11,12This study has also a few limitations that should be taken
into account in the interpretation of the results. Firstly, the
RAMQ database provides information on welfare recipients
and adherents to the RAMQ drug insurance plan only and not
for residents who are covered by a private drug insurance.
This led to a sample in which patients with high socio-
economic status were under represented. Lower socio-
economic status has been found to be associated with non-
adherence to asthma guidelines,1 and consequently we might
have over estimated non-adherence to the guidelines.
Secondly, the indication for which the combination therapy
has been prescribed is unknown. Although combination
therapy is only indicated for the treatment of asthma among
patients aged less than 45, some patients might have
received a combination therapy for another indication. In
order to minimize this problem we performed a sensitivity
analysis among patients who had a medical service for asthma
in the year preceding the first prescription of a combination
therapy. This analysis showed us that the percentage of
patients who used ICS previously increased by about 16%, but
despite this increase only 56% of the patients had filled a
prescription of ICS in the year preceding the initiation of the
combination therapy. Finally, as discussed previously, due to
the nature of the prescription database, it is not possible to
differentiate between patient’s behaviour and physician’s
prescribing habits. The absence of a filled prescription of ICS
prior to the first prescription of a combination product can be
due either to a patient that did not fill a prescription of ICS or
to the fact that the physician prescribed a combination
product as the initial long-term control asthma medication.
Another explanation for the absence of a filled prescription of
ICS prior to the combination therapy is the patient receiving
samples of ICS medications from his treating physician before
he decides to prescribe a combination therapy.
The results of this study show that combination therapy
has not been used according to the Canadian Asthma
Guidelines in a large proportion of patients. Prior markers
of asthma severity and uncontrolled disease were, as
expected, found to be associated with guidelines’ adher-
ence, but a non-negligible proportion of patients treated
with a combination therapy had no medical service for
asthma, had very mild asthma or received a combination
product as the initial controller therapy for asthma.
Increasing patients’ and physicians’ education about the
place of combination therapy in the treatment of asthma
might increase guidelines’ adherence. Education programs
could focus on patients treated in family medicine clinics
and in emergency departments in which non-adherence to
guidelines has been found to be more prevalent.
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